![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1461372
Àڱó» Àΰø¼öÁ¤(IUI) µð¹ÙÀ̽º ½ÃÀå : ÇöȲ ºÐ¼® ¹× ¿¹Ãø(2023-2030)Intrauterine Insemination Devices Market: Current Analysis and Forecast (2023-2030) |
¼¼°è ºÒÀÓÀÇ È®»êÀ¸·Î ÀÎÇØ Àڱó» Àΰø¼öÁ¤(IUI) µð¹ÙÀ̽º ½ÃÀåÀº ¾à 3.7%ÀÇ ¾ÈÁ¤ÀûÀÎ ¼ºÀåÀÌ ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é Àü ¼¼°è 6¸í Áß 1¸íÀÌ ÀÏ»ý µ¿¾È ºÒÀÓÀ» °æÇèÇÑ´Ù°í ÇÕ´Ï´Ù. È¿°úÀûÀÎ Ä¡·á¹ýÀ» ã±â À§ÇÑ ÀÓ»ó½ÃÇè Áõ°¡, ÀÇ·á ºÎ¹®¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡ µî ¿©·¯ °¡Áö ¿äÀÎÀÌ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î, Àڱó» Àΰø¼öÁ¤(IUI) µð¹ÙÀ̽ºÀÇ Ãâ½Ã°¡ °¡¼ÓÈµÇ¸é¼ È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â Àڱó» Àΰø¼öÁ¤(IUI) µð¹ÙÀ̽º ½ÃÀåÀ» ¾ÈÁ¤ÀûÀ¸·Î °ßÀÎÇϰí ÀÖ½À´Ï´Ù.
Á¦Ç° À¯Çü¿¡ µû¶ó ½ÃÀåÀº Àڱó» Àΰø¼öÁ¤(IUI) Ä«Å×ÅÍ¿Í Àڱó» Àΰø¼öÁ¤(IUI) Á¤ÀÚ ¼¼Ã´±â·Î ³ª´¹´Ï´Ù. Àڱó» Àΰø¼öÁ¤(IUI) Á¤ÀÚ ¼¼Ã´±â ½ÃÀåÀº ºÒÀÓ È¯ÀÚ Áõ°¡·Î ÀÎÇØ 2022³â ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. Àڱó» Àΰø¼öÁ¤(IUI) Á¤ÀÚ ¼¼Ã´Àº Àΰø¼öÁ¤½Ã Àڱÿ¡ »ðÀÔ ÇÒ Á¤ÀÚ¸¦ ÁغñÇÏ´Â °úÁ¤ÀÔ´Ï´Ù. ¿©±â¿¡´Â Á¤¾× »ùÇÿ¡¼ °Ç°ÇÏ°í ¿îµ¿¼ºÀÌ ÁÁÀº Á¤ÀÚ¸¦ ºÐ¸®Çϰí ÇÁ·Î½ºÅ¸±Û¶õµò, ¹ÚÅ׸®¾Æ ¹× Á×Àº Á¤ÀÚ¿Í °°Àº ÀáÀçÀûÀ¸·Î À¯ÇØÇÑ ¹°ÁúÀ» Á¦°ÅÇÏ´Â °ÍÀÌ Æ÷ÇԵ˴ϴÙ. µû¶ó¼ Á¦Ç° À¯Çü Áß Àڱó» Àΰø¼öÁ¤(IUI) Á¤ÀÚ ¼¼Ã´ ºÎ¹®Àº 2022³â Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÃÖÁ¾ »ç¿ëÀÚ¿¡ µû¶ó ½ÃÀåÀº º´¿ø, IVF Ŭ¸®´Ð, ±âŸ·Î ºÐ·ùµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È º´¿øÀÇ È¯ÀÚ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó Ŭ¸®´Ð ºÎ¹®ÀÌ ½ÃÀå¿¡¼ Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Ŭ¸®´ÐÀº Àڱó» Àΰø¼öÁ¤(IUI)(IUI) ¼ºñ½ºÀÇ ÁÖ¿ä Á¦°ø¾÷üÀ̱⠶§¹®¿¡ Ŭ¸®´Ð ºÎ¹®Àº Àڱó» Àΰø¼öÁ¤(IUI)(IUI) ÀåÄ¡ ½ÃÀå¿¡¼ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀÌ ºÎ¹®¿¡´Â ºÒÀÓ Å¬¸®´Ð, »ý½Ä ÀÇ·á ¼¾ÅÍ, º¸Á¶»ý½Ä¼ú(ART) ¼ºñ½º¸¦ Á¦°øÇÏ´Â º´¿øÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ ºÎ¹®¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â IUI ÀåÄ¡ÀÇ ±â¼ú ¹ßÀü, ºÒÀÓ Ä¡·á¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ´ëü Àӽйæ¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µîÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±ÔÁ¦ Á¤Ã¥, »óȯ ½Ã³ª¸®¿À ¹× ȯÀÚ ¼±È£µµ¿Í °°Àº ¿äÀεµ IUI ÀåÄ¡ ½ÃÀå¿¡¼ Ŭ¸®´Ð ºÎ¹®ÀÇ ¿ªÇп¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. µû¶ó¼ ¿¹Ãø ±â°£ µ¿¾È Ŭ¸®´Ð ºÎ¹®Àº ÃÖÁ¾ »ç¿ëÀÚ Áß ´õ ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
½ÃÀåÀ» ´õ Àß ÀÌÇØÇϱâ À§ÇØ ºÏ¹Ì(¹Ì±¹, ij³ª´Ù, ±âŸ ºÏ¹Ì), À¯·´(µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º, ½ºÆäÀÎ, ÀÌÅ»¸®¾Æ, ±âŸ À¯·´), ¾Æ½Ã¾ÆÅÂÆò¾ç(Áß±¹, ÀϺ», Àεµ, ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç), ±âŸ Áö¿ª¿¡¼ÀÇ ¼¼°è ÀÔÁö¸¦ ±âÁØÀ¸·Î ½ÃÀåÀ» ºÐ¼®ÇÕ´Ï´Ù. ºÐ¼®µË´Ï´Ù. ºÏ¹Ì´Â ºÒÀÓ È¯ÀÚ ±ÞÁõ, ÀÇ·áºñ Áõ°¡, Çõ½ÅÀûÀÎ ¹ßÀüÀ» µµÀÔÇϱâ À§ÇÑ ³ë·Â°ú ÅõÀÚ Áõ°¡·Î ÀÎÇØ 2022³â ÇöÀç ½Ã³ª¸®¿À¿¡¼ ½ÃÀåÀ» Áö¹èÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹¿¡ º»»ç¸¦ µÐ ¸ð½Ã º£À̺ñ(Mosie Baby)´Â 2023³â 12¿ù¿¡ °¡Á¤¿ë Àΰø¼öÁ¤ ŰƮÀÇ FDA ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. Á¤ºÎ ±â°üÀº ÀÌ Áö¿ªÀÇ »ç·Ê Áõ°¡¸¦ À§ÇØ ºÒÀÓ ÀÎ½Ä °³¼± ÇÁ·Î±×·¥À» ½ÃÀÛÇϰí ÀÖ½À´Ï´Ù. µû¶ó¼ 2022³â ½ÃÀå Á¡À¯À²Àº Áö¿ªº°·Î´Â ºÏ¹Ì°¡ Å« ºñÁßÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÌ ½ÃÀå¿¡¼ Ȱµ¿ÇÏ´Â ÁÖ¿ä ±â¾÷À¸·Î´Â CooperSurgical Fertility Company, Cook Group Incorporated, Vitrolife Sweden AB, Kitazato Corporation, FUJIFILM Irvine, Fujifilm Irvine, Rocket Medical plc, Thomas Medical, Famasys Inc. Scientific, MEDGYN PRODUCTS, INC., Rocket Medical plc., Thomas Medical, Famasys Inc. µîÀÌ ÀÖ½À´Ï´Ù.
Intrauterine insemination (IUI) is a fertility treatment where sperm is directly inserted into a woman's uterus to facilitate fertilization. It's often used when there are issues with sperm motility or when the cause of infertility is unexplained. It's a less invasive and less expensive option compared to in vitro fertilization (IVF). Intrauterine insemination (IUI) devices are specialized tools used by healthcare providers to perform the procedure. These devices are designed to facilitate the placement of sperm directly into the uterus, optimizing the chances of fertilization during the IUI procedure. A rising number of clinical trials and technological advancements are leading to the market's growth. Several other factors, such as rising research & development activities, rising healthcare expenditure, rising regulatory support, and a surge in government collaborations & partnerships are driving the intrauterine insemination devices market globally.
The Intrauterine Insemination Devices Market is expected to grow at a steady rate of around 3.7% owing to the growing prevalence of infertility globally. For instance, according to the World Health Organization, globally one in six people experience infertility in their lifetime. Several factors, including a rising number of clinical trials to find effective treatment, and rising investments in healthcare departments are driving the market's growth during the forecast period. Apart from this, the accelerated launch of intrauterine insemination devices has resulted in higher demand for effective treatment procedures which are also driving this market of intrauterine insemination devices at a steady rate.
Based on the product type, the market is bifurcated into intrauterine insemination catheters and intrauterine insemination sperm wash. The intrauterine insemination sperm wash segment dominated the market in the year 2022 owing to the rising cases of infertility. Intrauterine insemination sperm wash is a process used to prepare sperm for insertion into the uterus during the IUI procedure. It involves separating healthy, motile sperm from the semen sample and removing potentially harmful substances such as prostaglandins, bacteria, and dead sperm. Thus, among the product types, the intrauterine insemination sperm wash segment held a significant market share in 2022.
Based on the end user, the market is categorized into hospitals, IVF clinics, and others. The clinic segment is expected to hold a significant share of the market in the forecast period owing to the rising patient load in hospitals. The clinics segment plays a vital role in the intrauterine insemination (IUI) device market, as clinics are the primary providers of IUI services. This segment encompasses fertility clinics, reproductive health centers, and hospitals offering assisted reproductive technology (ART) services. Key factors influencing this segment include technological advancements in IUI devices, increasing awareness about fertility treatments, and rising demand for alternative conception methods. Additionally, factors such as regulatory policies, reimbursement scenarios, and patient preferences also impact the dynamics of the clinic segment within the IUI device market. Thus, the clinics category will witness a higher CAGR amongst end users during the forecast period.
For a better understanding, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is dominating the market in the current scenario of 2022 due to the surge in cases of infertility, rising healthcare expenditure, and rising initiatives and investments in introducing innovative advancements. For instance, in December 2023, U.S.-based Mosie Baby got FDA clearance for its at-home artificial insemination kit. Government organizations are initiating infertility awareness programs for the sake of the growing cases in the region. Thus, amongst regions, North America held a significant share of the market in 2022.
Some of the major players operating in the market include CooperSurgical Fertility Company; Cook Group Incorporated; Vitrolife Sweden AB; Kitazato Corporation; FUJIFILM Irvine Scientific; MEDGYN PRODUCTS, INC.; Rocket Medical plc.; Thomas Medical; Femasys Inc.; Allwin Medical Devices.